Recce Pharmaceuticals Ltd. · ASX:RCE

Recce Pharmaceuticals — Investor Presentation (September 2023)

38 slides from Recce Pharmaceuticals's investor presentation, September 2023

  1. Slide 1: Corporate Presentation

    Slide 1: Corporate Presentation

    Corporate Presentation ASX:RCE | FSE:R9Q September 2023

  2. Slide 2: About Recce Pharmaceuticals Ltd

    Slide 2: About Recce Pharmaceuticals Ltd

    About Recce Pharmaceuticals Ltd • Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) is developing a new class of Synthetic Anti-Infectives, protected by Composition of Matter Patent • Australian clinical-stage biotech company, with a United States presence • Strong pre-clinical data package demonstrati

  3. Slide 3: Board and Management Structure

    Slide 3: Board and Management Structure

    Board and Management Structure Dr John Prendergast – Chairman BSc (Hons), MSc (UNSW), PhD (UNSW), CSS (HU) US-based, current Chairman and Co-founder of Palatin Technologies, Inc. (NYSE: PTN) Michele Dilizia – Executive Director & Chief Scientific Officer BSc (Med Sci), Grad Dip Bus (Mkting), BA (Jou

  4. Slide 4: Platform Technology

    Slide 4: Platform Technology

    Platform Technology Recce’s products will treat systemic and local infections caused by ESKAPE pathogens, other resistant organisms or when the etiology of the infection is unknown • Very broad-spectrum coverage of bacteria with no signs of resistance • Extremely rapid onset of effect – measured in

  5. Slide 5: Strong Pipeline

    Slide 5: Strong Pipeline

    Strong Pipeline Over Various Indications and Upcoming Inflection Points Asset and Indications Discovery Pre-Clinical Phase I Phase II Phase III Market Route of Administration Serious/life threatening bacterial infections including sepsis Urinary tract infections R327 Intravenous* including urosepsis

  6. Slide 6: Sepsis – it's a big problem!

    Slide 6: Sepsis – it's a big problem!

    Sepsis – it’s a big problem! 2 What is Sepsis? Economic Impact Social Impact Sepsis is a life-threatening Is the most expensive Kills more people in the US inflammatory response to condition to treat in the than prostate, breast cancer infection that has spread in last 8 years5. and HIV/AIDS combine

  7. Slide 7: Sepsis Patient Journey

    Slide 7: Sepsis Patient Journey

    Sepsis Patient Journey Patient Presents at the Hospital Early treatment with an effective antibiotic is key to improving patient outcome • 1/3 of patients present non-specific symptoms, leading to delayed treatment and high mortality rate. MENINGITIS • Mortality from sepsis increases by as much as 8

  8. Slide 8: Urinary Tract Infections and Urosepsis

    Slide 8: Urinary Tract Infections and Urosepsis

    Urinary Tract Infections and Urosepsis The Infection In approximately 30% of all septic patients the • Urinary tract infection (UTI) is one of the most common infectious focus is localised in the urogenital tract infectious diseases • The most common pathogen causing UTIs is E. coli with 90% • More

  9. Slide 9: The Need for a New Class of Antibiotics: Synthetic Anti-Infectives

    Slide 9: The Need for a New Class of Antibiotics: Synthetic Anti-Infectives

    The Need for a New Class of Antibiotics: Synthetic Anti-Infectives • NO pre-formed natural superbugs. • Entirely man-made and designed with purpose. • Universal Mechanism of Action - does not succumb to resistance. • Broad Spectrum capability and maintains its activity even with repeated use. • Empo

  10. Slide 10: Independent Study Undertaken on R327 MoA

    Slide 10: Independent Study Undertaken on R327 MoA

    Independent Study Undertaken on R327 MoA1 By Leading Experts in Bacterial MoA Analysis Stage 1 Stage 2 R327 arrests cell growth and R327 disrupts bacterial cellular permeabilizes cell membranes energetics, depleting ATP • Novel mechanism which targets rapid access to and shut down of bacterial energ

  11. Slide 11: RECCE 327 Activity Against Escherichia coli

    Slide 11: RECCE 327 Activity Against Escherichia coli

    RECCE® 327 Activity Against Escherichia coli • E. coli grows fast. Eukaryotic cells healthy Without R327 R327 (3,000 ppm) and not affected. • R327 at 3,000 ppm shown to be highly effective against E. coli without affecting growing, healthy eukaryotic cells. • R327 rapidly and irreversibly shuts down

  12. Slide 12: RECCE 327 Activity Against Staphylococcus aureus

    Slide 12: RECCE 327 Activity Against Staphylococcus aureus

    RECCE® 327 Activity Against Staphylococcus aureus • S. aureus bacterial growth slower than E. coli, not Without R327 R327 (2,300 ppm) affecting eukaryotic cells. • R327 at 2,300 ppm shows to be highly effective against S. aureus without affecting growing, healthy eukaryotic cells. • R327 rapidly and

  13. Slide 13: R327 Faster Acting Than Existing Antibiotics

    Slide 13: R327 Faster Acting Than Existing Antibiotics

    R327 Faster Acting Than Existing Antibiotics No Prolonged Exposure Needed • R327 kills pathogenic bacteria at a faster rate. • R327 designed to work faster than all existing antibiotics, reinforced by MoA work undertaken by experts in their field. “R327 kills bacteria in conditions where other antib

  14. Slide 14: Bactericidal Effect of RECCE 327 on ESKAPE Pathogens

    Slide 14: Bactericidal Effect of RECCE 327 on ESKAPE Pathogens

    Bactericidal Effect of RECCE® 327 on ESKAPE Pathogens Control Control Control Control Control Control • Average time-kill curves of R327 at various concentrations against strains of ESKAPE pathogens (tested in duplicate) • Time-kill study was performed to determine the bacterial killing effect of R3

  15. Slide 15: Phase I Human Clinical Trial - Complete

    Slide 15: Phase I Human Clinical Trial - Complete

    Phase I Human Clinical Trial - Complete 120x dose amount* 6,000 mg ✓ • Study to assess IV infusion of RECCE® 327 in healthy male subjects as a single ascending dose. 80x dose amount* 4,000 mg ✓ • Randomized, double-blind, placebo-controlled, safety, tolerability and pharmacokinetics study. 60x dose

  16. Slide 16: RECCE 327 Concentrates Safely in the Urine

    Slide 16: RECCE 327 Concentrates Safely in the Urine

    RECCE® 327 Concentrates Safely in the Urine Concentration of R327 in Ratio Urine Compared to Urine/Plasma - Plasma 16x 17x 14x 9x In over 60 healthy 21x subjects 16x – R327 primary route of elimination appears to be through – Opportunities for therapeutic in array of UTIs (uncomplicated the kidney t

  17. Slide 17: RECCE 327 - Intravenous formulation – Phase I

    Slide 17: RECCE 327 - Intravenous formulation – Phase I

    RECCE® 327 - Intravenous formulation – Phase I Summary of Results – All Primary Endpoints Achieved ü No serious adverse events (SAEs) or deaths were reported in this study. ü No clinically significant changes were noted in any hematology parameter(s) in any cohort during the course of the study. ü N

  18. Slide 18: RECCE Kills Quickly in the Urine

    Slide 18: RECCE Kills Quickly in the Urine

    RECCE® 327 Kills Quickly in the Urine E. coli ATCC 25922 Treated with RECCE® 327 in Urine 10.00 • R327 in the presence of human urine was able to have a fast (near minutes) effect against E. coli 9.00 and irreversible Viable Bacteria (log CFU/ml) 8.00 • Bacteria could not be revived post-treatment V

  19. Slide 19: Topical RECCE 327 – Phase I/II

    Slide 19: Topical RECCE 327 – Phase I/II

    Topical RECCE® 327 – Phase I/II Patient examples from ongoing Burn Wound trial • Patients suffered major burn injury. • Multiple bacterial species in and surrounding wound. • Growth swabs with organisms including pathogens from the ESKAPE group of bacteria. Pre-treatment, significant Post R327 treat

  20. Slide 20: Patient Case Study – TGA Special Access Scheme Category A

    Slide 20: Patient Case Study – TGA Special Access Scheme Category A

    Patient Case Study – TGA Special Access Scheme Category A Day 0 Day 0 Day 0 After 24 hours After 30 days Pre-treatment First Recce Gel Application Post Treatment Post Treatment infection Gel Applied Complete • Patient Y unresponsive to 4 x daily Cephalexin for 10 days – Infection spreading and hospi

  21. Slide 21: Patient Case Study – TGA Special Access Scheme Category A

    Slide 21: Patient Case Study – TGA Special Access Scheme Category A

    Patient Case Study – TGA Special Access Scheme Category A Pre-Treatment Day 7 Day 10 Day 14 Day 0 – Recce treatment Day 7 – Recce treatment Day 10 – Recce treatment Day 14 – Recce treatment Significant bacterial infection Initial redness and swelling No signs of infection, no signs of pus Wound impr

  22. Slide 22: Patient Case Study – TGA Special Access Scheme Category A

    Slide 22: Patient Case Study – TGA Special Access Scheme Category A

    Patient Case Study – TGA Special Access Scheme Category A Pre-Treatment Day 7 Day 14 Day 21 Day 0 – Pre-treatment wound swab Day 7 – Recce treatment Day 14 – Recce treatment Day 21 – Recce treatment Growing culture of Gram-positive and Initial redness and swelling of the No signs of bacterial growth

  23. Slide 23: Patient Case Study – TGA Special Access Scheme Category A

    Slide 23: Patient Case Study – TGA Special Access Scheme Category A

    Patient Case Study – TGA Special Access Scheme Category A Pre-Treatment Day 3 Day 7 Significant bacterial infection Redness and swelling Left femoral Day 0 – Pre-treatment Day 3 – Recce treatment Day 7 – Recce treatment Significant bacterial infection, redness and Initial redness and swelling minimi

  24. Slide 24: Patient Case Study – TGA Special Access Scheme Category A

    Slide 24: Patient Case Study – TGA Special Access Scheme Category A

    Patient Case Study – TGA Special Access Scheme Category A Pre-Treatment Day 3 Day 7 Day 1 – Pre-treatment Day 3 – Recce treatment Day 7 – Recce treatment Osteomyelitis (serious infection of the bone), signs of Wound drying up with infection clearing, toe Wound completely dried up, no signs of biofil

  25. Slide 25: Phase I/II Diabetic Foot Ulcer (DFU) Clinical Trial

    Slide 25: Phase I/II Diabetic Foot Ulcer (DFU) Clinical Trial

    Phase I/II Diabetic Foot Ulcer (DFU) Clinical Trial Clinical Trial Overview Outpatient Nurses Appointed • Human Research Ethics approval received • Patients enrolled in Phase I/II now supported • Phase I/II to assess safety and efficacy of R327 by in-home (out-patient) nurses trained in on mild skin

  26. Slide 26: Robust Worldwide Intellectual Property Portfolio

    Slide 26: Robust Worldwide Intellectual Property Portfolio

    Robust Worldwide Intellectual Property Portfolio Recce’s patent portfolio contains over 40 patents and patent applications in the world’s major markets. Patent Patent Patent Expiry Expiry Expiry Filed Family 1 Family 2 Family 3 Family 1 group relates to the Company’s Unique and Highly Australia ✓ 20

  27. Slide 27: Pre-Clinical Study Outlook

    Slide 27: Pre-Clinical Study Outlook

    Pre-Clinical Study Outlook • Recce’s new Anti-Infective Research (AIR) Unit – Located within Murdoch Children’s Research Institute, one of the top three children’s research institutes worldwide – Fit-for-purpose laboratory space with a dedicated Murdoch Children’s team with access to infectious dise

  28. Slide 28: Manufacturing & Scalability

    Slide 28: Manufacturing & Scalability

    Manufacturing & Scalability Manufacturing facility in Sydney’s Macquarie Park • Raw materials plentiful and cheap – few $/Kg • No expensive waste – 99.9% product yield • Automated manufacture process taking approx. 1 hour, 500 doses produced per automated run • This in-house pilot facility provides

  29. Slide 29: Multiple Upcoming Clinical Milestones

    Slide 29: Multiple Upcoming Clinical Milestones

    Multiple Upcoming Clinical Milestones Topical R327 Burn Wounds Key inflection points Burn Wounds H1: Initiate Phase I/II Q4 23: Readout of Burn Wound Infection Phase I/II Burn Wound Clinical Trial- Initiated Infection Trial DFU DFU Q4 23: Readout of Phase H1: Initiate Phase I/II DFU I/II DFU Trial C

  30. Slide 30: Investment Highlights

    Slide 30: Investment Highlights

    Investment Highlights Recce Pharmaceuticals Ltd is a clinical-stage biotech company with a new class of novel synthetic anti-infectives Proprietary first-in-class, broad-spectrum anti-infectives against bacteria Multiple clinical indications and formulations in Phase I and II addressing unmet medica

  31. Slide 31: Thank you

    Slide 31: Thank you

    Thank you James Graham Managing Director and Chief Executive Officer Recce Pharmaceuticals Ltd ASX:RCE; FSE:R9Q +61 2 9256 2505 james.graham@recce.com.au recce.com.au

  32. Slide 32: Appendix

    Slide 32: Appendix

    eve recce.com.au Appendix 31

  33. Slide 33: Empowering Clinicians with a New Class of Antibiotics

    Slide 33: Empowering Clinicians with a New Class of Antibiotics

    Empowering Clinicians with a New Class of Antibiotics The need for new antibiotics has never been greater Physician perspectives on R327 • Initial resistance to use new approved drugs due to antibiotic resistance “We have so few options when patients have difficult pathogens. • “New antibiotics, abl

  34. Slide 34: Recently Approved Antibiotics – Benchmark for Pricing

    Slide 34: Recently Approved Antibiotics – Benchmark for Pricing

    Recently Approved Antibiotics – Benchmark for Pricing Anticipated Pricing Benchmarks1 USD $25,000 – $30,000 • Though Xigris (activated protein C) was pulled from the market in 2011, its pricing represents a potential premium benchmark for a novel sepsis agent • Fetroja, a recently approved agent for

  35. Slide 35: Successfully Completing a Clinical Trial Phase Can Lead to Significant Share Price Increase

    Slide 35: Successfully Completing a Clinical Trial Phase Can Lead to Significant Share Price Increase

    Successfully Completing a Clinical Trial Phase Can Lead to Significant Share Price Increase Case studies: Other antibiotic companies Price (US$) Volume (m) • Positive top line results from a global, pivotal Oct 2015: Ann. mixed results Phase III clinical trial of solithromycin oral $2 50.00 from 2nd

  36. Slide 36: Successfully Completing a Clinical Trial Phase Can Lead to Significant Share Price Increase

    Slide 36: Successfully Completing a Clinical Trial Phase Can Lead to Significant Share Price Increase

    Successfully Completing a Clinical Trial Phase Can Lead to Significant Share Price Increase Case studies: Other antibiotic companies Price (US$) Volume (m) • In December 2016, Achaogen announces $3 0.00 60 .0 positive results in Phase III cUTI and CRE clinical trials of Plazomicin. $2 5.00 50 .0 • E

  37. Slide 37: Large strategics are also paying attention

    Slide 37: Large strategics are also paying attention

    Large strategics are also paying attention Case studies: Partnering antibiotic assets creates value GSK and Spero Therapeutics announce exclusive licence US$66 million upfront and Up to US$525 million in potential agreement for late-stage antibiotic that may treat complicated UTIs milestones plus ro

  38. Slide 38: Many recent deals within the anti-infectives space

    Slide 38: Many recent deals within the anti-infectives space

    Many recent deals within the anti-infectives space have seen larger companies with an entrenched presence acquiring smaller Biotech's Key Recent Deals in Infectious Disease Companies Involved Deal Details Total Value Key Takeaways • Amplyx was developing therapies for patients with • Deal Date: Apri

Source: Internet Archive copy of recce.com.au

More decks from Recce Pharmaceuticals Ltd.

All 45 Recce Pharmaceuticals decks